We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study for Safety and Efficiency of Therapeutic Angiogenesis for Patients With Limb Ischemia by Transplantation of Human Cord Blood Mononuclear Cell

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified May 2007 by Samsung Medical Center.
Recruitment status was:  Recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT00518934
First Posted: August 21, 2007
Last Update Posted: August 21, 2007
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Samsung Medical Center
  Purpose
The purpose of this study is to analyze the safety and efficiency of therapeutic angiogenesis for patients with limb ischemia by transplantation of human cord blood mononuclear cells.

Condition Intervention Phase
Ischemia Other: Study for safety and efficiency of therapeutic angiogenesis for patients with limb ischemia by transplantation of human cord blood mononuclear cell Phase 1 Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Supportive Care

Further study details as provided by Samsung Medical Center:

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   up to 60 Years   (Child, Adult)
Sexes Eligible for Study:   All
Criteria

Inclusion Criteria:Patients with ischemic symptoms such as claudication, rest pain or nonhealing ischemic wound

  • Without evidence of improvement in response to conventional medical therapy
  • Not candidates for surgical intervention or radiologic intervention

Exclusion Criteria:

  • Malignant disease
  • More than 60 years old
  • Other significant medical conditions, including diabetes mellitus, hypertension, hyperlipidemia, etc.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00518934


Contacts
Contact: Dong-Ik Kim, Professor 82-2-3410-3467 dikim@skku.edu

Locations
Korea, Republic of
Samsung Medical Center, Sungkyunkwan University School of Medicine Recruiting
Seoul, Korea, Republic of, 135-710
Contact: Dong-Ik Kim, Professor    82-2-3410-3467    dikim@skku.edu   
Sponsors and Collaborators
Samsung Medical Center
Investigators
Study Director: Dong-Ik Kim, Professor Professor of division of vascular surgery, Samsung Medical Center, Sungkyunkwan University of School of Medicine
  More Information

Publications:
ClinicalTrials.gov Identifier: NCT00518934     History of Changes
Other Study ID Numbers: 2007-04-064
First Submitted: August 19, 2007
First Posted: August 21, 2007
Last Update Posted: August 21, 2007
Last Verified: May 2007

Keywords provided by Samsung Medical Center:
Safety and efficiency of angiogenesis for patients with limb
ischemia by transplantation of human cord blood mononuclear
cells

Additional relevant MeSH terms:
Ischemia
Pathologic Processes